Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (874)	8/19/2001 3:46:40 PM
From: JEB	Read Replies (1) \| Respond to of 1137

I agree with you 90%. Except the, "...how much debt they can lend." You and I both agree on the enormous potential of a winning drug. The company that holds a promising candidate gets money offered from many different directions in search of that big pay day. Big private and VC money carries major clout with many of the houses. Why did 'TheStreet' articles happen? Why did the 'Forbes' article happen? Don't both of these articles opinion contradict one another? Food for thought, JEB BTW - those same professionals talking about 'fundamental, P/E, and EPS ...etc, would give their right arm for a biotech with a blockbuster drug just approved for marketing and 500 million in debt to get it there. You and I both know if you wait for the biotech stock to become profitable, it is too late. You missed the train.